Companies House 2025-01-01 2025-12-31 2025-12-31 false true iso4217:GBP xbrli:pure 10244199 2024-01-01 2024-12-31 10244199 2025-12-31 10244199 2025-01-01 2025-12-31 10244199 2024-12-31 10244199 curr:PoundSterling 2025-01-01 2025-12-31 10244199 uk-bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 10244199 uk-bus:FRS102 2025-01-01 2025-12-31 10244199 uk-bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 10244199 uk-bus:AbridgedAccounts 2025-01-01 2025-12-31 10244199 uk-bus:RegisteredOffice 2025-01-01 2025-12-31 10244199 uk-bus:Director40 2025-01-01 2025-12-31 10244199 uk-bus:Director1 2025-01-01 2025-12-31 10244199 uk-bus:Director2 2025-01-01 2025-12-31 10244199 uk-bus:Director3 2025-01-01 2025-12-31 10244199 uk-bus:Director4 2025-01-01 2025-12-31 10244199 uk-bus:Director5 2025-01-01 2025-12-31 10244199 uk-bus:Director6 2025-01-01 2025-12-31 10244199 uk-bus:Director7 2025-01-01 2025-12-31 10244199 uk-bus:Director8 2025-01-01 2025-12-31 10244199 uk-bus:Director9 2025-01-01 2025-12-31 10244199 uk-bus:Director10 2025-01-01 2025-12-31 10244199 uk-bus:Director11 2025-01-01 2025-12-31 10244199 uk-bus:Director12 2025-01-01 2025-12-31 10244199 uk-bus:Director13 2025-01-01 2025-12-31 10244199 uk-bus:Director14 2025-01-01 2025-12-31 10244199 uk-bus:Director15 2025-01-01 2025-12-31 10244199 uk-bus:Director16 2025-01-01 2025-12-31 10244199 uk-bus:Director17 2025-01-01 2025-12-31 10244199 uk-bus:Director18 2025-01-01 2025-12-31 10244199 uk-bus:Director19 2025-01-01 2025-12-31 10244199 uk-bus:Director20 2025-01-01 2025-12-31 10244199 uk-bus:CompanySecretary1 2025-01-01 2025-12-31 10244199 core:AfterOneYear 2025-12-31 10244199 core:AfterOneYear 2024-12-31 10244199 core:WithinOneYear 2025-12-31 10244199 core:WithinOneYear 2024-12-31 10244199 core:WithinOneYear 2025-01-01 2025-12-31 10244199 core:AfterOneYear 2025-12-31 10244199 core:AfterOneYear 2024-12-31 10244199 core:AfterOneYear 2025-01-01 2025-12-31 10244199 core:ShareCapital 2025-12-31 10244199 core:ShareCapital 2024-12-31 10244199 core:SharePremium 2025-12-31 10244199 core:SharePremium 2024-12-31 10244199 core:OtherReservesSubtotal 2025-12-31 10244199 core:OtherReservesSubtotal 2024-12-31 10244199 core:RevaluationReserve 2025-12-31 10244199 core:RevaluationReserve 2024-12-31 10244199 core:RetainedEarningsAccumulatedLosses 2025-12-31 10244199 core:RetainedEarningsAccumulatedLosses 2024-12-31 10244199 core:Associate1 2025-01-01 2025-12-31 10244199 core:Associate1 2024-12-31 10244199 core:Associate1 2025-12-31 10244199 core:Associate2 2025-01-01 2025-12-31 10244199 core:Associate2 2024-12-31 10244199 core:Associate2 2025-12-31 10244199 core:Associate3 2025-01-01 2025-12-31 10244199 core:Associate3 2024-12-31 10244199 core:Associate3 2025-12-31 10244199 core:Associate4 2025-01-01 2025-12-31 10244199 core:Associate4 2024-12-31 10244199 core:Associate4 2025-12-31 10244199 core:Associate5 2025-01-01 2025-12-31 10244199 core:Associate5 2024-12-31 10244199 core:Associate5 2025-12-31 10244199 core:Associate6 2025-01-01 2025-12-31 10244199 core:Associate6 2024-12-31 10244199 core:Associate6 2025-12-31 10244199 core:Associate7 2025-01-01 2025-12-31 10244199 core:Associate7 2024-12-31 10244199 core:Associate7 2025-12-31 10244199 core:Associate8 2025-01-01 2025-12-31 10244199 core:Associate8 2024-12-31 10244199 core:Associate8 2025-12-31 10244199 core:Associate9 2025-01-01 2025-12-31 10244199 core:Associate9 2024-12-31 10244199 core:Associate9 2025-12-31 10244199 core:Associate10 2025-01-01 2025-12-31 10244199 core:Associate10 2024-12-31 10244199 core:Associate10 2025-12-31 10244199 core:Associate11 2025-01-01 2025-12-31 10244199 core:Associate11 2024-12-31 10244199 core:Associate11 2025-12-31 10244199 core:Associate12 2025-01-01 2025-12-31 10244199 core:Associate12 2024-12-31 10244199 core:Associate12 2025-12-31 10244199 core:Associate13 2025-01-01 2025-12-31 10244199 core:Associate13 2024-12-31 10244199 core:Associate13 2025-12-31 10244199 core:Associate14 2025-01-01 2025-12-31 10244199 core:Associate14 2024-12-31 10244199 core:Associate14 2025-12-31 10244199 core:Associate15 2025-01-01 2025-12-31 10244199 core:Associate15 2024-12-31 10244199 core:Associate15 2025-12-31 10244199 core:Associate16 2025-01-01 2025-12-31 10244199 core:Associate16 2024-12-31 10244199 core:Associate16 2025-12-31 10244199 core:Associate17 2025-01-01 2025-12-31 10244199 core:Associate17 2024-12-31 10244199 core:Associate17 2025-12-31 10244199 core:Associate18 2025-01-01 2025-12-31 10244199 core:Associate18 2024-12-31 10244199 core:Associate18 2025-12-31 10244199 core:Associate19 2025-01-01 2025-12-31 10244199 core:Associate19 2024-12-31 10244199 core:Associate19 2025-12-31 10244199 core:Associate20 2025-01-01 2025-12-31 10244199 core:Associate20 2024-12-31 10244199 core:Associate20 2025-12-31 10244199 core:Associate1 2025-01-01 2025-12-31 10244199 core:Associate2 2025-01-01 2025-12-31 10244199 core:Associate3 2025-01-01 2025-12-31 10244199 core:Associate4 2025-01-01 2025-12-31 10244199 core:Associate5 2025-01-01 2025-12-31 10244199 core:Associate6 2025-01-01 2025-12-31 10244199 core:Associate7 2025-01-01 2025-12-31 10244199 core:Associate8 2025-01-01 2025-12-31 10244199 core:Associate9 2025-01-01 2025-12-31 10244199 core:Associate10 2025-01-01 2025-12-31 10244199 core:Associate11 2025-01-01 2025-12-31 10244199 core:Associate12 2025-01-01 2025-12-31 10244199 core:Associate13 2025-01-01 2025-12-31 10244199 core:Associate14 2025-01-01 2025-12-31 10244199 core:Associate15 2025-01-01 2025-12-31 10244199 core:Associate16 2025-01-01 2025-12-31 10244199 core:Associate17 2025-01-01 2025-12-31 10244199 core:Associate18 2025-01-01 2025-12-31 10244199 core:Associate19 2025-01-01 2025-12-31 10244199 core:Associate20 2025-01-01 2025-12-31 10244199 uk-bus:Director1 1 2025-01-01 2025-12-31 10244199 uk-bus:Director1 1 2024-12-31 10244199 uk-bus:Director1 1 2025-12-31 10244199 uk-bus:Director2 2 2025-01-01 2025-12-31 10244199 uk-bus:Director2 2 2024-12-31 10244199 uk-bus:Director2 2 2025-12-31 10244199 uk-bus:Director1 3 2025-01-01 2025-12-31 10244199 uk-bus:Director1 3 2024-12-31 10244199 uk-bus:Director1 3 2025-12-31 10244199 uk-bus:Director4 4 2025-01-01 2025-12-31 10244199 uk-bus:Director4 4 2024-12-31 10244199 uk-bus:Director4 4 2025-12-31 10244199 uk-bus:Director5 5 2025-01-01 2025-12-31 10244199 uk-bus:Director5 5 2024-12-31 10244199 uk-bus:Director5 5 2025-12-31 10244199 uk-bus:Director6 6 2025-01-01 2025-12-31 10244199 uk-bus:Director6 6 2024-12-31 10244199 uk-bus:Director6 6 2025-12-31 10244199 uk-bus:Director7 7 2025-01-01 2025-12-31 10244199 uk-bus:Director7 7 2024-12-31 10244199 uk-bus:Director7 7 2025-12-31 10244199 uk-bus:Director8 8 2025-01-01 2025-12-31 10244199 uk-bus:Director8 8 2024-12-31 10244199 uk-bus:Director8 8 2025-12-31 10244199 uk-bus:Director9 9 2025-01-01 2025-12-31 10244199 uk-bus:Director9 9 2024-12-31 10244199 uk-bus:Director9 9 2025-12-31 10244199 uk-bus:Director10 10 2025-01-01 2025-12-31 10244199 uk-bus:Director10 10 2024-12-31 10244199 uk-bus:Director10 10 2025-12-31 10244199 uk-bus:Director11 11 2025-01-01 2025-12-31 10244199 uk-bus:Director11 11 2024-12-31 10244199 uk-bus:Director11 11 2025-12-31 10244199 uk-bus:Director12 12 2025-01-01 2025-12-31 10244199 uk-bus:Director12 12 2024-12-31 10244199 uk-bus:Director12 12 2025-12-31 10244199 uk-bus:Director13 13 2025-01-01 2025-12-31 10244199 uk-bus:Director13 13 2024-12-31 10244199 uk-bus:Director13 13 2025-12-31 10244199 uk-bus:Director14 14 2025-01-01 2025-12-31 10244199 uk-bus:Director14 14 2024-12-31 10244199 uk-bus:Director14 14 2025-12-31 10244199 uk-bus:Director15 15 2025-01-01 2025-12-31 10244199 uk-bus:Director15 15 2024-12-31 10244199 uk-bus:Director15 15 2025-12-31 10244199 uk-bus:Director16 16 2025-01-01 2025-12-31 10244199 uk-bus:Director16 16 2024-12-31 10244199 uk-bus:Director16 16 2025-12-31 10244199 uk-bus:Director17 17 2025-01-01 2025-12-31 10244199 uk-bus:Director17 17 2024-12-31 10244199 uk-bus:Director17 17 2025-12-31 10244199 uk-bus:Director18 18 2025-01-01 2025-12-31 10244199 uk-bus:Director18 18 2024-12-31 10244199 uk-bus:Director18 18 2025-12-31 10244199 uk-bus:Director19 19 2025-01-01 2025-12-31 10244199 uk-bus:Director19 19 2024-12-31 10244199 uk-bus:Director19 19 2025-12-31 10244199 uk-bus:Director20 20 2025-01-01 2025-12-31 10244199 uk-bus:Director20 20 2024-12-31 10244199 uk-bus:Director20 20 2025-12-31 10244199 1 2025-01-01 2025-12-31 10244199 2 2025-01-01 2025-12-31 10244199 3 2025-01-01 2025-12-31

# LONDON HORMONE CLINIC LIMITED

## Company Registration Number:
10244199 (England and Wales)

## Unaudited abridged accounts for the year ended 31 December 2025

## Period of accounts

## Start date: 01 January 2025

## End date: 31 December 2025

# LONDON HORMONE CLINIC LIMITED

## Contents of the Financial Statements

for the Period Ended 31 December 2025

Balance sheet |
Notes |

# LONDON HORMONE CLINIC LIMITED

## Balance sheet

As at 31 December 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Fixed assets
Tangible assets: | 3 | 101,644 | 141,476
Total fixed assets: |  | 101,644 | 141,476
Current assets
Debtors: |  | 105,651 | 121,348
Cash at bank and in hand: |  | 112,619 | 129,271
Total current assets: |  | 218,270 | 250,619
Creditors: amounts falling due within one year: | 4 | (164,479) | (289,180)
Net current assets (liabilities): |  | 53,791 | (38,561)
Total assets less current liabilities: |  | 155,435 | 102,915
Provision for liabilities: |  | (13,102) | (8,372)
Total net assets (liabilities): |  | 142,333 | 94,543
Capital and reserves
Called up share capital: |  | 1,000 | 1,000
Profit and loss account: |  | 141,333 | 93,543
Shareholders funds: |  | 142,333 | 94,543

The notes form part of these financial statements

# LONDON HORMONE CLINIC LIMITED

## Balance sheet statements

For the year ending 31 December 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 27 June 2026
and signed on behalf of the board by:

Name: Janine Toledano
Status: Director

The notes form part of these financial statements

# LONDON HORMONE CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

## Turnover policy

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

## Tangible fixed assets and depreciation policy

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows: Property improvements - over 5 years Plant and machinery - over 4 years

## Other accounting policies

Debtors Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Creditors Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method. Taxation A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted. Provisions Provisions (i.e. liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably. Operating Leases Rentals paid under operating leases are recognised as an expense on a straight line basis over the lease term. Pensions Contributions to defined contribution plans are expensed in the period to which they relate.

# LONDON HORMONE CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 2. Employees

| 2025 | 2024
--- | --- | ---
Average number of employees during the period | 10 | 10

# LONDON HORMONE CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 3. Tangible Assets

| Total
--- | ---
Cost | £
At 01 January 2025 | 219,672
Additions | 995
At 31 December 2025 | 220,667
Depreciation |
At 01 January 2025 | 78,196
Charge for year | 40,827
At 31 December 2025 | 119,023
Net book value |
At 31 December 2025 | 101,644
At 31 December 2024 | 141,476

# LONDON HORMONE CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 4. Creditors: amounts falling due within one year note

Creditors: amounts falling due within one year 2025 Trade creditors £31,714 Taxation and social security costs £30,816 Other creditors £101,949 Total £164,479 2024 Trade creditors £3,494 Taxation and social security costs £136 Other creditors £285,550 Total £289,180

# LONDON HORMONE CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 5. Financial commitments

Other Financial Commitments Total future minimum payments under non-cancellable operating leases £225,000 (2024 - £315,000)

# LONDON HORMONE CLINIC LIMITED

## Notes to the Financial Statements

for the Period Ended 31 December 2025

## 6. Loans to directors

Name of director receiving advance or credit: | Jan Toledano
Description of the loan: | At the year end the amount due to the director was £59,971 (2024 - £60,670). The balance is unsecured, interest free and repayable on demand.
£
Balance at 01 January 2025 |  | 60,670
Advances or credits repaid: |  | 699
Balance at 31 December 2025 |  | 59,971